Rituximab in primary LPHD (RIPL) - first line therapy for patients with lymphocyte predominant Hodgkin's disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Rituximab (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms RIPL
- 12 Aug 2008 Biomarkers information updated
- 10 Aug 2008 The expected completion date for this trial is now 1 Nov 2007 as reported by ClinicalTrials.gov.
- 25 Feb 2008 Status changed from recruiting to completed.